Merck & Co. (MRK) : Excalibur Management Corp reduced its stake in Merck & Co. by 0.15% during the most recent quarter end. The investment management company now holds a total of 92,156 shares of Merck & Co. which is valued at $5,053,835 after selling 140 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Apr 25, 2016.Merck & Co. makes up approximately 4.51% of Excalibur Management Corp’s portfolio.
Merck & Co. opened for trading at $54.85 and hit $55.36 on the upside on Monday, eventually ending the session at $55.3, with a gain of 0.84% or 0.46 points. The heightened volatility saw the trading volume jump to 96,78,915 shares. Company has a market cap of $153,472 M.
Other Hedge Funds, Including , Hudson Valley Investment Advisors Inc Adv boosted its stake in MRK in the latest quarter, The investment management firm added 687 additional shares and now holds a total of 64,173 shares of Merck & Co. which is valued at $3,519,247. Merck & Co. makes up approx 1.14% of Hudson Valley Investment Advisors Inc Adv’s portfolio.Sadoff Investment Management reduced its stake in MRK by selling 460 shares or 9.6% in the most recent quarter. The Hedge Fund company now holds 4,331 shares of MRK which is valued at $245,741. Merck & Co. makes up approx 0.03% of Sadoff Investment Management’s portfolio.Schaper Benz Wise Investment Counsel Incwi reduced its stake in MRK by selling 8,341 shares or 9.59% in the most recent quarter. The Hedge Fund company now holds 78,620 shares of MRK which is valued at $4,460,899. Merck & Co. makes up approx 0.82% of Schaper Benz Wise Investment Counsel Incwi’s portfolio.M. Kraus Co boosted its stake in MRK in the latest quarter, The investment management firm added 25 additional shares and now holds a total of 8,560 shares of Merck & Co. which is valued at $480,558. Merck & Co. makes up approx 0.33% of M. Kraus Co’s portfolio.Integrated Investment Consultants boosted its stake in MRK in the latest quarter, The investment management firm added 61 additional shares and now holds a total of 31,386 shares of Merck & Co. which is valued at $1,762,010. Merck & Co. makes up approx 1.00% of Integrated Investment Consultants’s portfolio.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.Merck & Co. was Downgraded by BofA/Merrill to ” Neutral” on Jan 27, 2016.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.